IO Biotech, Inc. Common Stock (IOBT)
IO Biotech, Inc. (IOBT) is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for the treatment of cancer and autoimmune diseases. The company leverages its proprietary immune modulation platform, referred to as Immuno-Oncology Biotech (IOBT), to design therapies that stimulate the body's immune system to target disease more effectively. Founded to advance personalized and combination immune treatments, IO Biotech aims to improve patient outcomes through its novel therapeutic candidates.
Company News
The market for untreated metastatic melanoma is poised for strong growth, with over 10 companies driving innovation through advanced immunotherapies, targeted treatments, and combination therapies.
As of Jan. 22, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here’s the latest list of major overbought players in this sector. SOPHiA GENETICS SA (NASDAQ: SOPH) On Jan. 8, SOPHiA GENETICS announced a collaboration with Exactis Innovation on multimodal data analytics. The company’s stock jumped around 14% over the past six months and has ...
IO Biotech (IOBT) falls 25% despite achieving the clinical milestone of enrolling 225 patients in the advanced melanoma study evaluating the IO102-IO103/Keytruda combo.